» Articles » PMID: 29225330

Huntingtin Gene Repeat Size Variations Affect Risk of Lifetime Depression

Abstract

Huntington disease (HD) is a severe neuropsychiatric disorder caused by a cytosine-adenine-guanine (CAG) repeat expansion in the HTT gene. Although HD is frequently complicated by depression, it is still unknown to what extent common HTT CAG repeat size variations in the normal range could affect depression risk in the general population. Using binary logistic regression, we assessed the association between HTT CAG repeat size and depression risk in two well-characterized Dutch cohorts─the Netherlands Study of Depression and Anxiety and the Netherlands Study of Depression in Older Persons─including 2165 depressed and 1058 non-depressed persons. In both cohorts, separately as well as combined, there was a significant non-linear association between the risk of lifetime depression and HTT CAG repeat size in which both relatively short and relatively large alleles were associated with an increased risk of depression (β = -0.292 and β = 0.006 for the linear and the quadratic term, respectively; both P < 0.01 after adjustment for the effects of sex, age, and education level). The odds of lifetime depression were lowest in persons with a HTT CAG repeat size of 21 (odds ratio: 0.71, 95% confidence interval: 0.52 to 0.98) compared to the average odds in the total cohort. In conclusion, lifetime depression risk was higher with both relatively short and relatively large HTT CAG repeat sizes in the normal range. Our study provides important proof-of-principle that repeat polymorphisms can act as hitherto unappreciated but complex genetic modifiers of depression.

Citing Articles

and CAG triplet repeat sizes: exploring their role in the disease risk and cancer comorbidity in Parkinson's disease.

Perez-Oliveira S, Alvarez I, Menendez-Gonzalez M, Duarte-Herrera I, Blazquez-Estrada M, Castilla-Silgado J Brain Commun. 2025; 7(1):fcaf060.

PMID: 39974178 PMC: 11837329. DOI: 10.1093/braincomms/fcaf060.


Small striatal huntingtin inclusions in patients with motor neuron disease with reduced penetrance and intermediate HTT gene expansions.

Roos A, Stenvall E, Kockum E, Gronlund K, Alstermark H, Wuolikainen A Hum Mol Genet. 2024; 33(22):1966-1974.

PMID: 39270726 PMC: 11555821. DOI: 10.1093/hmg/ddae137.


Mutant Huntingtin Drives Development of an Advantageous Brain Early in Life: Evidence in Support of Antagonistic Pleiotropy.

Neema M, Schultz J, Langbehn D, Conrad A, Epping E, Magnotta V Ann Neurol. 2024; 96(5):1006-1019.

PMID: 39115048 PMC: 11496017. DOI: 10.1002/ana.27046.


The pathobiology of depression in Huntington's disease: an unresolved puzzle.

Jellinger K J Neural Transm (Vienna). 2024; 131(12):1511-1522.

PMID: 38349403 DOI: 10.1007/s00702-024-02750-w.


Expanding horizons of tandem repeats in biology and medicine: Why 'genomic dark matter' matters.

Hannan A Emerg Top Life Sci. 2023; .

PMID: 38088823 PMC: 10754335. DOI: 10.1042/ETLS20230075.


References
1.
Penninx B, Beekman A, Smit J, Zitman F, Nolen W, Spinhoven P . The Netherlands Study of Depression and Anxiety (NESDA): rationale, objectives and methods. Int J Methods Psychiatr Res. 2008; 17(3):121-40. PMC: 6878352. DOI: 10.1002/mpr.256. View

2.
Aziz N, Pijl H, Frolich M, van der Graaf A, Roelfsema F, Roos R . Increased hypothalamic-pituitary-adrenal axis activity in Huntington's disease. J Clin Endocrinol Metab. 2009; 94(4):1223-8. DOI: 10.1210/jc.2008-2543. View

3.
Shirbin C, Chua P, Churchyard A, Lowndes G, Hannan A, Pang T . Cortisol and depression in pre-diagnosed and early stage Huntington's disease. Psychoneuroendocrinology. 2013; 38(11):2439-47. DOI: 10.1016/j.psyneuen.2012.10.020. View

4.
Molendijk M, Spinhoven P, Polak M, Bus B, Penninx B, Elzinga B . Serum BDNF concentrations as peripheral manifestations of depression: evidence from a systematic review and meta-analyses on 179 associations (N=9484). Mol Psychiatry. 2013; 19(7):791-800. DOI: 10.1038/mp.2013.105. View

5.
Langbehn D, Brinkman R, Falush D, Paulsen J, Hayden M . A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin Genet. 2004; 65(4):267-77. DOI: 10.1111/j.1399-0004.2004.00241.x. View